Kamada Launches Annual Dividend Policy After Record 2025 Results

The latest update is out from Kamada ( (IL:KMDA) ).

On March 11, 2026, Kamada announced that its board had declared a cash dividend of $0.25 per share, or about $14.4 million in total, following record revenue and profitability for full-year 2025. The dividend, to be paid on April 6, 2026 to shareholders of record as of March 23, 2026, marks the implementation of a newly adopted annual cash dividend policy under which the company intends, subject to board discretion and legal limits, to distribute at least 50% of its annual net income.

Management framed the payout as evidence of confidence in Kamada’s business prospects and liquidity, indicating that the company expects to maintain investment in commercial growth, business development and potential M&A while returning cash to shareholders. The move signals a more shareholder-friendly capital allocation stance that could enhance Kamada’s appeal to income-focused investors, while its strong 2025 performance underpins guidance for continued double-digit, organic, profitable growth in 2026.

The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs2791.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

More about Kamada

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and other biologics for rare and serious conditions. Its portfolio includes six FDA-approved plasma-derived products, additional rabies immunoglobulin and anti-snake venom therapies, and in-licensed drugs distributed in Israel and the MENA region. The company also operates three U.S. plasma collection centers and pursues M&A and partnerships to expand its marketed portfolio and sustain profitable growth.

Average Trading Volume: 84,630

Technical Sentiment Signal: Strong Buy

Current Market Cap: ILs1.61B

For detailed information about KMDA stock, go to TipRanks’ Stock Analysis page.